Low-Dose 2D/3D Orthopedic Imaging System Adopted by Leading U.S. Hospital
CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)-- EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that Massachusetts General Hospital (MGH) has installed the EOS® low-dose 2D/3D imaging system for orthopedic clinical use. MGH, based in Boston, Mass., is one of the nation’s leading research hospitals and is ranked among the top U.S. hospitals for orthopedic care.1
The EOS imaging system provides full-body images of patients in a natural standing or seated position, both in 2D and 3D. It automatically calculates a broad range of clinical parameters essential to diagnosis and surgical planning, allowing for more informed diagnosis and treatment of orthopedic conditions, including scoliosis, degenerative spine conditions and lower limb joint conditions. Notably, EOS offers high-quality images while delivering a radiation dose that is nine times lower than that of computed radiography X-ray2 and 20 times lower than basic CT scans.3
Marie Meynadier, CEO of EOS imaging, said, “The adoption of EOS at Massachusetts General Hospital speaks to the critical role of the technology in orthopedic care. EOS is replacing traditional radiographic systems for obtaining weight-bearing surveys of the entire spine and lower extremities, while helping to improve patient throughput and technologist productivity and providing 3D information unavailable until now. We are pleased that the system will be available to orthopedists in the MGH community, who are at the forefront of clinical care and medical research, as we continue our focus on expanding patient access to our leading 2D/3D imaging technology at centers across the U.S.”
MGH is the oldest and largest teaching hospital of Harvard Medical School and conducts the largest hospital-based research program in the U.S. It was named the number 1 hospital in America by U.S. News & World Report in its 2012-13 “America’s Best Hospitals” ranking.
About EOS imaging:
The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 49 sites and more than 250,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 59 people, including an R&D team of 21 engineers and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge (Massachusetts), in Montreal (Canada) and in Germany.
For more information, please visit the website : www.eos-imaging.com.
EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 3rd quarter of 2012 on 15 November 2012 (after market).
1 U.S. News & World Report. America’s Best Hospitals: Top-Ranked Hospitals for Orthopedics, via http://health.usnews.com/best-hospitals/rankings/orthopedics
2 S. Parent et al. “Diagnostic imaging of spinal deformities: Reducing patients radiation dose with a new slot-scanning x-ray imager.” Spine. April 2010, 35 (9): 989.
3 D. Folinais et al. “Lower Limb Torsional assessment: comparison EOS/CT Scan.” JFR 2011.
Anne Renevot, CFO
Tel.: +33 (0)1 55 25 61 24
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91
The Ruth Group (US)
Press Relations - Lisa Cook
ALIZE RP (Europe)
Relations presse - Caroline Carmagnol
Tél : +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
Source: EOS imaging